To determine whether rigorous insulin therapy, which normalized the routinely measured plasma llplds, also reversed qualitative abnormalities In the composition of llpoprotelns In noninsulin-dependent diabetes mdlltus (NIDDM), we studied 18 NIDDM patients (eight men and 10 women) before and 2 months after Intensive insulin therapy. Glycosylated hemoglobin levels (11.7% vs. 8.7%), plasma trtglyceride (TG) (250±91 vs. 164±56 mg/dl, p<0.001), and cholesterol (214±43 vs. 198±31 mg/dl,p<0.025) all fell, and both HDU cholesterol and HDL, cholesterol Increased (59.1% and 10.9%, respectively, p<0.001). However, abnormalities In two indices of lipoprotein surface constituents, which were present before insulin therapy, remained so thereafter. The first of these, the new cardiovascular risk factor, the plasma free cholesterol/lecithin ratio, which was Increased before treatment, fell only slightly after therapy (pro-therapy 1.02±0.29 vs. post-therapy 0.90±0.17, p<0.4; reference group, 0.83±0.14), and remained elevated In very low density lipoprotein (VLDL) and low density lipoprotein (LDL). Secondly, the sphlngomyelln/lectthln ratio, an Index of the surface rigidity of llpoprotelns, was abnormal before treatment In VLDL, HDLj, and HDLj, and this alteration persisted after Insulin therapy In HDL, (p<0.001). Lipoprotein core Hold abnormalities were also present before treatment the TG/cholesteryl ester ratio was reduced In VLDL and Increased in LDL, HDL* and HDL,. Rigorous Insulin therapy Improved, but failed to fully correct, this disturbance. In HDU, apollpoproteln (apo) A-l Increased significantly (p<0.005), and apo A-ll and apo E were unchanged; In contrast, In HDL,, apo A-l was unchanged, and apo A-ll and apo E both decreased ( 
D
isturbances in lipoprotein transport and overt hyperllpldemia are frequently encountered in noninsulindependent diabetes mellitus (NIDDM) 123 and are believed to contribute to the diabetic patient's increased cardiovascular risk. 4 Recent studies have shown that rigorous short-term therapy with Insulin corrects these perturbations and results in a variety of potentially antiatherogenic, quantitative changes in serum lipids and lipoproteins in patients with NIDDM. 6 These include decreases in plasma trlglyceride (TG) and very low density lipoprotein (VLDL)-TG and Increases in various estimates of the mass of HDL 2 , the high density lipoprotein (HDL) subtraction most closely associated with protection against coronary heart disease. 0 Since it is now known and put the patients at increased cardiovascular risk, optimal treatment should reverse these qualitative disturbances as well. While the quantitative changes observed after intensive insulin treatment are believed to be beneficial, the impact of this therapy in NIDDM on lipoprotein surface and core lipid composition is unknown.
To address this question, we performed detailed lipoprotein analyses in a group of poorly controlled NIDDM patients whose metabolic and serum lipid responses to intensive insulin therapy have been recently reported in this journal. 5 
Methods

Subjects
The group described in this study includes 18 of the 19 previously reported 8 NIDDM patients (10 postmenopausaJ women and eight men) who attended the Diabetes Clinic of the Helsinki University Hospital. As conditions of recruitment, they all had fasting hyperglycemia (>200 mg/dl); glycosylated hemoglobin (HbA,) concentrations exceeding 11 %; were, receiving maximal treatment with the oral hypoglycemic agents, glibenclamide (15 to 20 mg/day) and metformln (1 to 2.0 mg/day); and had fasting C-peptide levels exceeding 1.0 ^g/l-Informed consent was obtained. All volunteers for the study agreed to be hospitalized initially and 1 to 2 months later. All subjects were seen on one or two occasions during this interval by a diabetes nurse educator and were instructed about diet and glucose monitoring. The mean age of the patients was 58±6 years (mean±SD, range 42 to 68 years), and their relative weights averaged 125%±18% (range 95% to 154%). The women were somewhat more obese than .the men (relative body weight, 132%±15% vs. 116%±18%). The mean duration of diabetes was 9.6±1.0 years (mean±SEM), range 2 to 18 years. On the basis of their medical histories, physical examinations, and routine laboratory studies, including those of thyroid function, they were, except for their diabetes, considered to be in reasonable health. No patient had a positive test for urinary albumin. The mean serum creatjnine of the group was 87±12 ^mol/l (range 71 to 118 /imol/1). Ten patients were mildly hypertensive, and six had a history of prior myocardial infarction or coronary heart disease. Four patients were taking nitrates; five, antihypertensrves; seven others, diuretics; and six, beta blockers. these medications were continued at the same dose throughout the study.
Study Design
While in hospital on a metabolic ward after entry Into the study, all patients received a weight-maintaining sucrose-free diet (35% fat, 45% carbohydrate, 20% protein) , and their oral medications were continued. After this 3-day period of stabilization, adipose tissue biopsy and the heparin test for lipoprotein lipase (LPL) measurement as previously reported 5 were performed on consecutive mornings after an overnight fast of 10 to 12 hours. Upoprotein analyses were performed on blood samples drawn before the heparin test was performed. After these pretreatment studies were obtained, oral antidiabetic agents were discontinued, and insulin therapy was initiated. These same tests were repeated under identical conditions 7 weeks later. All patients were instructed to continue their usual level of physical activity and to daily record their body weights.
Insulin Therapy
Diabetic control was achieved by two or three injections daily with regular insulin alone (Actrapid, Novo Industri A/S) or in conjunction with intermediate acting Insulin (Protophan, Novo Industri A/S). Therapy was initiated with 30 to 40 units of intermediate insulin per day Injected before breakfast and at 9:00 P.M. Additional regular insulin was added before breakfast and dinner to achieve good glycemic control (fasting glucose less than 140 mg/dl and postprandial glucose levels less than 180 mg/dl). Ten days to 2 weeks were required before insulin doses and glucose levels were stabilized.
All patients employed home glucose monitoring (Hypocount MX glucometer; Oriola, Helsinki, Finland). Eight patients spent 3 to 4 days each week during the period of insulin therapy on the metabolic ward; 10 were followed as outpatients only after glycemic control had been achieved. This group was seen two to three times weekly to assess their home blood glucose profiles. Daily caloric intake was adjusted according to the disappearance of glucosuria to assure that a stable body weight was maintained.
Glycemic Control
The adequacy of diabetic control was monitored by twice daily blood glucose measurements obtained at 7:30 A.M. (fasting) and at 4:00 P.M. and with 24-hour urinary glucose determinations. Meals were served at 7:30 A.M., 11 :30 A.M., and 4:30 P.M., and snacks, at 10:00 A.M., 2:00 P.M., and 8:00 P.M.
Plasma Uplds and Upoprotein Analysis
Upoprotein fractions were separated by sequential flotation in an ultracentrifuge 8 (Beckman L8-70, Beckman, Palo Alto, CA). First, chytomlcrons were isolated from fresh plasma by centrffugatJon for 30 minutes at 18 000 rpm at 4°C in a T.50.3 Beckman rotor. The infranatant then was overtayered with 0.16 M NaCI and 1 mM of ethylenediamlnetetraacetic add (d=1.006 g/ml), and VLDL was isolated by tube slicing following an 18-hour spin at 38 000 rpm. The density of the remaining plasma was then adjusted to 1.019 g/ml with a mixture of KBr (353 g/T) and NaCI (153 g/l), and intermediate density lipoproteins (IDL) were then isolated by ultracentrtfugation for 24 hours at 38 000 rpm at 4°C. The density of the IDL bottom fraction was then raised to 1.063 g/l with the same KBr-NaCI mixture (d=1.335 g/ml) utilized In a previously reported study 5 ; LDL was isolated by spinning for 24 hours at 38 000 rpm. HDL 2 and HDL 3 were isolated by differential precipitation with dextran sulfate from previously unthawed frozen plasma. 9 The HDL subtractions isolated by this technique have been shown to correspond closely to those separated by ultracentrifugation. 10 The following analyses of lipoprotein composition were performed on all fractions with the exception of IDL
Assay of Upolytlc Enzymes
Heparin-releasable LPL was estimated in needle aspirates of gluteal subcutaneous adipose tissue by using labeled triolein as substrate as previously described.
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LPL and hepatic lipase (HL) activities were measured immunochemicalty in plasma at 5 and 15 minutes after the bolus injection of heparin (100 lU/kg body weight, Vrtrum, Stockholm, Sweden) by utilizing a specific antiserum against HL in the assay of LPL 12 The HL activity was estimated with a substrate containing 1 M NaCI to inactivate the LPL
Analytical Methods
All the following analyses with the exception of previously estimated HbA, were performed in this laboratory in the same assay on samples of whole plasma and lipoprotein fractions isolated in Helsinki that had been kept frozen (-70°C) and on the HDL fractions isolated in this laboratory by precipitation from the whole plasma samples. Plasma glucose was measured with a glucose oxidase method. HbA, (reference range, 6.0% to 8.5%) was assayed with a chromatographic microcolumn method (Isolab Incorporated, Akron, OH). Cholesterol and TG were measured in whole plasma and in the lipoprotein fractions by using kits from Boehringer Mannheim. Free cholesterol was quantitiated in an aliquot of whole plasma and in the same lipoprotein fractbns with a kit in which cholesterol ester hydrolase was omitted. Apollpoproteins A-l, A-ll, 13 B, 14 and E 15 were measured by immunoassay. The four major lipoprotein phospholipids, lysolecithin, sphlngomyelin (S), lecithin (L), and phosphatidyl ethanolamine (PE), were estimated in whole plasma and in each lipoprotein fraction after their extraction by a thin-layer chromatographic procedure 16 employing activated silica gel plates (0.5 mm in thickness) and a solvent system of chforoform/methanol/ acetic acid/water of 25:15:4:2 by volume. Each phospholipid spot was scraped into glass tubes, and the lipid phosphorus was determined by the modified Bartlett procedure. 17 The reference values for lipoprotein composition displayed in the tables were obtained from 35 healthy nonobese nondiabetic normolipidemic hospital and laboratory medical center employees in Chicago and included 15 women and 20 men from 25 to 60 years of age whose weights were within 10% of their ideal body weight determined from a Metropolitan Life Insurance table.
Statistical Analysis
The means for each variable were compared by the paired t test for independent samples, and the linear relationships between variables were estimated by using Spearman rank correlation coefficients. No comparisons were made with the values for the reference group.
Results
Metabolic Parameters
After insulin treatment, all indices of glycemic control improved significantly (Table 1 ). The average dose of insulin administered to achieve control was 0.75±0.06 U/kg/day. Body weight increased slightly after treatment (75.1 ±2.4 vs. 76.4±2.3 kg, p<0.05).
Serum Uplds, Upoprotelns, and Upolytlc Enzymes
Since concentrations of plasma neutral and phospholipids and apolipoproteins (apo) were not significantly different in men and women in the reference group or in the NIDDM subjects before or after insulin therapy, all data were expressed as a single pooled group for each of the two groups respectively. After treatment, TG, cholesterol, and free cholesterol (FC) all fell significantly (Table 1). The relative decline In FC exceeded that of L (Table 2 ) with the result that the FC/L ratio, which was abnormally increased before insulin, fell after therapy but remained higher than that of the reference group.
In VLDL, all core and surface lipids were abnormally increased initially (Tables 2 and 3 ) and also fell significantly after insulin treatment. Insulin had little effect, however, on the proportion of major lipids present in the lipoprotein core and surface; the TG/cholesteryl ester (CE) and FC/L ratios were decreased before insulin and remained so thereafter. In contrast, the S/L ratio of VLDL, which was low before insulin therapy, was restored to normal.
In LDL, the FC/L and TG/CE ratios were both abnormally increased before rigorous therapy, and neither was significantly altered by it. Thus, these parameters of LDL surface and core remained higher than the values of the reference group despite intensive management. Here, In contrast to VLDL the S/L ratio was similar to that of the reference group before treatment and was not appreciably affected by insulin (Tables 2 and 3 ).
In the HDL subtractions, several changes were observed after intensive therapy. Treatment was associated with significant increases In not only HDU cholesterol but also its major phospholipids S and L FC (Table 2) , and in apo A-l (Table 4) ; no net change occurred in HDU, apo A-ll, or apo E levels. Before insulin treatment, HDL 2 -apo A-ll levels, however, were lower in men; treatment was associated with an increase only in men (after: men 9.8±5.5 mg/dl, p<0.025; women 11.6±5.8, p=ns). Nevertheless, their HDU ap° A-l/A-ll ratios were unchanged by insulin therapy. The FC/L ratio, however, which was subnormal before treatment, actually fell further (p<0.001) after Insulin treatment. The TG/CE ratio, which was abnormally increased before insulin therapy, fell significantly in HDU (-59.8%) but remained elevated. Similar, though not identical, changes in HDU composition followed insulin treatment. Here, total and esterified cholesterol both increased (p< 0.001, Table 3 ). Although HDU FC showed no net change, the FC/L ratio Increased significantly (p<0.05) to normal levels. In contrast, the S/L ratio, which was increased before treatment, was unchanged by it. As noted In HDL 2 , TG declined and cholesterol rose, with the result that the TG/CE ratio fell significantly (p<0.001), remaining, however, elevated after therapy (Table 3) . Although HDU phospholipid and apo A-l levels were not altered by insulin therapy, apo A-ll and apo E both decreased significantly (p<0.005).
Plasma post-heparin LPL was unchanged after insulin therapy (before, 21.6±5.9; after, 22.5±5.9 fiirni FFA/ ml/hour). On the other hand, post-heparin HL fell (before, 25.2±12.6; after, 20.7±9.3/imol FFA/ml/hour, p<0.1), but the result did not reach statistical significance. There was no demonstrable correlation between either HbA, or glucose and: 1) hepatic or adipose tissue lipase activities and 2) the FC/L ratios in whole plasma or VLDL before or after 
Discussion
Rigorous treatment of NIDDM patients with Insulin has been shown to lower total plasma and VLDL triglyceride concentrations, 81810 ' 20 total plasma and LDL cholesterol, 519 and apo B levels, 5 and to increase the HDU subtraction of HDL 5 Since most past epidemiologlc studies in nondiabetic populations have shown that cardiovascular risk correlates directly with increases in total plasma and LDL cholesterol 21 -22 and TG, 2324 or inversely with HDL/cholesterol, 25 -26 these changes observed in plasma lipids and lipoproteins after insulin treatment in NIDDM patients are presumed to be beneficial. It has been generally assumed that reducing plasma lipid levels when they are abnormally high will reduce cardiovascular risk in diabetic populations, as has been shown in the hyperiipidemic patients in the Upid Research Clinics Coronary Primary Prevention Trial 27 and the Helsinki Heart Study. 28 No clinical trial, however, has yet been undertaken to determine whether this assumption obtains in patients with diabetes mellitus.
The risk of accelerated development of atherosclerotic cardiovascular complications is substantially increased in NIDDM, and the presence of hypertension, smoking, and high cholesterol clearly potentiates this risk. 4 However, the basis for premature atherosclerosis in treated NIDDM patients who have no risk factors other than diabetes remains unclear. Our data indicate that well-controlled NIDDM patients have potentially atherogenic qualitative abnormalities in lipoprotein surface and core lipid composition, which persist even after their plasma lipid levels have been normalized by aggressive treatment with insulin. It should be pointed out, however, that despite the aggressive therapeutic measures, normalization of either glucose or insulin levels was not likely to have been attained. Consequently, despite the remarkable improvement in overall diabetic control and in the plasma lipid profile of these patients, the persisting abnormalities may relate in part to Individual metabolic differences among patients, such as obesity or inherited dyslipidemia, or to factors such as persisting hyperglycemia and the intensive insulin therapy itself.
The specific disturbances in composition that we observed after insulin include an enrichment in FC relative to L in VLDL and LDL, with the result that the FC/L ratio in these lipoproteins and plasma increased compared to our reference group. This observation is significant because Kuksis et al. 29 found in a Lipid Research Clinics study in Toronto that the FC/L ratio is a potent predictor for cardiovascular risk comparable to HDL cholesterol. This increase in the FC/L ratio is in keeping with our previous findings in normollpidemlc insulin-dependent diabetes mellitus (IDDM) subjects. 3031 While the enrichment we observed in lipoprotein FC is consistent with evidence that cholesterol synthesis increases In NIDDM patients, 32 its persistence after apparently successful diabetic therapy suggests that it may not be readily reversed.
Precisely how an increased FC/L ratio in plasma lipoproteins adversely affects cardiovascular risk is unknown. It is possible that when lipoproteins are oversaturated with FC, their fluidity and stability may decrease, and their physicochemical properties and behavior may change. Indeed, Fielding 33 has presented evidence that several key steps in reverse cholesterol transport may be adversely affected when lipoproteins are enriched in FC. Specifically, FC-enriched VLDL and LDL from NIDDM patients, which have increased FC/phospholipid ratios, were shown to have an impaired capacity to participate in neutral lipid exchange and to accept CE in transfer (CET) from HDL 34 Moreover, these workers found that intact plasma from NIDDM was a poor acceptor of cholesterol from cultured cells. 35 In this study, we observed that the TG/CE ratios of both LDL and HDL were increased. This finding is consistent with the enrichment of their core lipids with TG in NIDDM shown earlier. 3837 As we found with the abnormalities in surface lipid composition, these changes also persisted after marked improvement in glycemic control. In contrast to the increase in the TG/CE ratio present in LDL and HDL core lipid content, a reciprocal decrease was present in VLDL, which was relatively depleted in TG and enriched in CE. As a result, the TG/CE ratio of NIDDM VLDL before treatment was substantially lower than that of our reference group and remained so after insulin therapy. While LPL, HL, and neutral lipid exchange reactions all contribute to the remodeling of lipoproteins that normally takes place in plasma, 38 a disturbance in the latter system would appear to best explain the composite of altered TG/CE ratios observed. Specifically, if the heteroexchange of CE from HDLfor TG from VLDL (i.e., CET) were accelerated, a relative enrichment of VLDL with CE reflected by a decreased TG/CE ratio as we have observed would result. Indeed, our finding that CET was accelerated in both IDDM 39 and NIDDM patients (unpublished observations) suggests that facilitated neutral lipid exchange reactions underlie these changes in VLDL and HDL core lipid composition. Since intensive insulin therapy improved their hepatic and LPL activities, 5 persistence of the abnormal TG/CE ratios in HDL increases the likelihood that accelerated CET was a major mechanism contributing to this compositional disturbance.
The most extensive changes in lipoprotein composition after rigorous treatment were observed in HDL. While surface and core lipid abnormalities were present before insulin therapy in both subfractions, treatment had differing effects on each. Total and estertfled cholesterol both increased on an absolute basis and relative to TG in both HDL subfractions. The magnitude of this change, however, and the accompanying reduction in the TG/CE ratio after insulin was greater in HDU than in HDL 3 . Among the abnormalities present in surface lipids in HDL 2 before treatment, the elevated S/L ratio declined to normal after insulin; the reduced pretreatment FC/L ratio, on the other hand, fell even further. In HDL3, the S/L ratio was abnormally increased before insulin therapy and was unaffected by it; here the reduced pre-treatment FC/L ratio rose significantly to normal levels.
Interesting responses to insulin therapy also were observed in HDL apoprotein composition. In HDU, apo A-l increased significantly relative to A-ll, suggesting that the number of particles containing only apo A-l in the whole group had increased. Differences, however, were present in the absolute levels of apo A-ll in HDL: in men and women before insulin treatment In contrast to HDL 2 apo A-l levels, which were similar in both sexes before treatment and rose after insulin treatment, apo A-ll levels were lower in men than in women before insulin, and only rose significantly in men. In men, no change at all was observed in the apo A-l/A-ll ratio In HDLj; in NIDDM women, this ratio increased in eight out of nine subjects, suggesting that insulin therapy may have increased the proportion of their HDU particles containing apo A-l only. This difference implies that despite their menopausal status, their HDL response to insulin therapy was affected by hormonal differences that existed between the middle-aged men and women in this study. The significance of this apparent sex-related response in HDU composition with regard to atherosclerosis is unclear.
In contrast to the differences observed in HDU, in HDL, the apo A-l was unchanged, and apo A-ll actually declined, which is consistent with insulin affecting a reduction in the number of particles containing both apo A-l and A-ll and a relative increase in those containing apo A-l only. Since HDL particles containing both A-l and A-ll are believed to be less effective promoters of efflux of free cholesterol from cells than those containing A-l only,* 0 a relative reduction in this subpopulation of HDL particles and ah increase in those with only apo A-l is theoretically beneficial, since it would facilitate this important first step in reverse cholesterol transport.
Although only 10% to 15% of circulating HDL particles in humans contain apo E, 41 they are significant because they can bind to cells expressing apo B,E (LDL) receptors with a higher affinity than LDL itself 42 and thus can deliver cholesterol to cells. Since apo E associates with small HDL particles in humans 43 before they acquire cholesterol and enlarge in size, the changes we have observed in HDL apo E concentrations after Insulin therapy are of interest. Here, too, the effects of intensive treatment on apo E-containing particles differed in each HDL subtraction. In HDU, no net change in apo E occurred during insulin treatment. However, since the total number of particles increased, the relative number of those containing apo E appears to have declined. On the other hand, in HDU the apo E content actually fell without a significant change in total mass or particle number. Thus, insulin therapy appears to have reduced the number and amount of apo E-containing HDL particles. Our finding that insulin treatment also had disparate effects on both the protein and lipid composition of the HDL subfractions is consistent with evidence that the HDU and HDU subfractions are subject to differing regulatory influences. 41 Since adipose tissue LPL and HL are both insulin-sensitive enzyme systems, 6 it is likely that they also made some contribution to the changes we observed in HDL composition.
In this collaborative study, neutral lipid measurements were performed on frozen, previously isolated lipoprotein fractions in Helsinki (excluding IDL) and HDL subfractions precipitated from frozen whole plasma in Chicago. Certain discrepancies exist in the actual values obtained for some of the lipoprotein TG and cholesterol values and in the HDL subfractions between our data and that previously published. 6 The directional changes, however, are fully consistent in the two sets of data and do not alter our major conclusions.
Despite the anti-atherogenic profiles achieved in their whole plasma and in some lipoprotein lipids with vigorous insulin therapy in this cohort of Finnish NIDDM patients, a number of potentially significant abnormalities in apoprotein and surface and core lipid composition persisted, which may be helpful for understanding the predisposition of diabetic populations to accelerated atherogenesis. The disturbances we have found may alter gradients normally present on NIDDM lipoproteins, which influence the directional fluxes of their constituents in transfer reactions. In addition, these alterations may not only impair the normal movement of FC between lipoproteins and cells, but they may also alter the sites of catabolism of the particles themselves. If these data can be extrapolated to NIDDM patients elsewhere, they suggest that the persist-ing compositional derangements of the type we find after treatment may have far ranging clinical consequences in NIDDM patients, in spite of good clinical control.
